Technical Analysis for SNPX - Synaptogenix, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Crossed Above 20 DMA | Bullish | -2.48% | |
MACD Bullish Signal Line Cross | Bullish | -2.48% | |
Wide Bands | Range Expansion | -2.48% | |
Up 3 Days in a Row | Strength | -2.48% | |
Wide Bands | Range Expansion | 9.44% |
Alert | Time |
---|---|
Possible NR7 | about 9 hours ago |
Possible Inside Day | about 9 hours ago |
60 Minute Opening Range Breakout | about 10 hours ago |
20 DMA Support | about 12 hours ago |
Down 3% | about 13 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/28/2024
Synaptogenix, Inc. Description
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Neuroscience Rare Diseases Alzheimer's Disease Stroke Neurodegenerative Diseases Multiple Sclerosis Amyotrophic Lateral Sclerosis Neurodegeneration Neurodegenerative Disorders Fragile X Syndrome Traumatic Brain Injury
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.88 |
52 Week Low | 0.1411 |
Average Volume | 880,084 |
200-Day Moving Average | 0.43 |
50-Day Moving Average | 0.20 |
20-Day Moving Average | 0.20 |
10-Day Moving Average | 0.19 |
Average True Range | 0.03 |
RSI (14) | 50.98 |
ADX | 18.17 |
+DI | 20.92 |
-DI | 14.26 |
Chandelier Exit (Long, 3 ATRs) | 0.21 |
Chandelier Exit (Short, 3 ATRs) | 0.24 |
Upper Bollinger Bands | 0.24 |
Lower Bollinger Band | 0.16 |
Percent B (%b) | 0.52 |
BandWidth | 40.78 |
MACD Line | 0.00 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0016 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.21 | ||||
Resistance 3 (R3) | 0.21 | 0.21 | 0.21 | ||
Resistance 2 (R2) | 0.21 | 0.20 | 0.21 | 0.21 | |
Resistance 1 (R1) | 0.20 | 0.20 | 0.20 | 0.20 | 0.21 |
Pivot Point | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 |
Support 1 (S1) | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 |
Support 2 (S2) | 0.19 | 0.19 | 0.19 | 0.18 | |
Support 3 (S3) | 0.18 | 0.19 | 0.18 | ||
Support 4 (S4) | 0.18 |